



April 23, 2015

## **Dr. Dale Schenk to Participate on Expert Panel at World Medical Innovation Forum: Neurosciences**

DUBLIN, Ireland, April 23, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs, today announced that Dale Schenk, PhD, the Company's President and Chief Executive Officer, will participate on an expert panel at the World Medical Innovation Forum: Neurosciences, which is being held at the Westin Copley Place in Boston, MA, on April 28, 2015 at 8:30 a.m. EDT.

Dr. Schenk will participate on the panel entitled, "The Alzheimer's Phoenix: New Technologies, New Economics." Other members of the panel include Michael Hutton, PhD, Chief Scientific Officer of Neurodegenerative Diseases for Eli Lilly & Co; Brad Hyman, MD, PhD, Director of the Massachusetts General Hospital Alzheimer's Disease Research Center and John B. Penney Jr. Professor of Neurology, Harvard Medical School; Roger Nitsch, PhD, Director of the Division of Psychiatry Research at the University of Zurich; and, Dennis Selkoe, MD, Co-Director of the Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and the Vincent and Stella Coates Professor of Neurologic Diseases, Harvard Medical School. The panel will be moderated by Rudolph Tanzi, PhD, Director of Genetics and Aging Research Unit of the Massachusetts General Institute for Neurodegenerative Disease & Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard Medical School.

### **About Prothena**

Prothena Corporation plc is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs for the potential treatment of diseases that involve amyloid or cell adhesion. The Company is developing antibody-based product candidates that target a number of potential indications including AL amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and psoriasis and other inflammatory diseases (PRX003).

For more information, please visit the Company's web site at [www.prothena.com](http://www.prothena.com).

CONTACT: Investors: Tran Nguyen, CFO

650-837-8535, [IR@prothena.com](mailto:IR@prothena.com)

Media: Angela Bitting

925-202-6211, [angela.bitting@prothena.com](mailto:angela.bitting@prothena.com)